Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05735366 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT05735366 is a Phase 1 study that has completed, run by Chugai Pharmaceutical. The registered enrollment target is 22 participants.
The verdict
NCT05735366, a Phase 1 study, has completed, sponsored by Chugai Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced or metastatic solid tumors.
Interventions
- DRUG SAIL66
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2026-01-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05735366
The ClinicalTrials.gov registry entry for NCT05735366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAIL66 is the first listed.
NCT05735366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05735366 about?
NCT05735366 is a clinical study titled "A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors". This is a Phase 1 dose-escalation and expansion study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of SAIL66 in patients with CLDN6-positive locally advanced or metastatic solid tumors.
What is the current status of trial NCT05735366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-04-17. Estimated completion is 2026-01-26.
What interventions are being tested in trial NCT05735366?
The interventions under investigation include: SAIL66 (DRUG).
Who is sponsoring clinical trial NCT05735366?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.